Kymera Therapeutics Presents New Preclinical Data for KT-579 Kymera Therapeutics, Inc. announced the presentation of new preclinical data for KT-579, a first-in-class, oral IRF5 degrader, …
Rates of Physician Attrition From Clinical Practice Have Risen Since 2013 A recent study found that the rate of physician attrition from c…
Isuzu FA Trophy Second Round Proper Draw Confirmed The draw for the Isuzu FA Trophy Second Round Proper has been announced, with 40 matche…
New Toronto Transit Station to Open A new station serving GO Transit's Kitchener Line and UP Express is set to open in weeks. Metro…
Dracula Technologies Secures €30M in Series A Round Valence, France-based Dracula Technologies has announced the successful completion of …
World Treadmill Championships to Debut in 2026 The first-ever World Treadmill Championships, dubbed RUN X, will take place over 5km in 202…
Fi Europe 2025: A Key Return to Paris Registration is now open for Fi Europe 2025, celebrating its 30th edition in Paris from 2-4 December…
In the Age of Ozempic: Accessibility and Cost The effectiveness and cost of weight loss drugs like Ozempic, Wegovy, and Mounjaro have been…
Study Claims Ozempic Lowers Biological Age Researchers reveal that GLP-1 medication Ozempic may reduce biological age, offering new hope i…
Navigating Complex Injury Cases Dealing with a serious injury case can be stressful and confusing, with nearly 70 percent of personal inju…
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study Neumora Therapeutics, Inc. has initiated a Phase 1 single-ascending do…